Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Badoux, Xavier C. [1 ]
Keating, Michael J. [1 ]
O'Brien, Susan [1 ]
Wierda, William G. [1 ]
Faderl, Stefan [1 ]
Estrov, Zeev [1 ]
Pasia, Manolo [1 ]
Lerner, Susan [1 ]
Sargent, Rachel L. [2 ]
Kantarjian, Hagop M. [1 ]
Ferrajoli, Alessandra [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：448 / 448
页数：1
相关论文
共 50 条
  • [1] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [2] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
  • [3] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [4] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
  • [5] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Hillmen, Peter
    Mahadevan, Daruka
    Buehler, Andreas
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David D.
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    Moutouh-de Parseval, Laure
    Hallek, Michael
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
  • [6] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [7] Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis
    Choi, Michael Y.
    Castro, Januario E.
    Hoff, Sheila
    Li, Hongying
    Rassenti, Laura
    James, Danelle F.
    Messer, Karen
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [8] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
  • [9] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Odetola, Oluwatobi
    Ma, Shuo
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (05) : 130 - 143
  • [10] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Oluwatobi Odetola
    Shuo Ma
    Current Hematologic Malignancy Reports, 2023, 18 : 130 - 143
12345